Company news

Zelira Therapeutics Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Phase 1 Opioid Reduction Clinical Trial Fully Enrolled

February 26, 2020

Zelira Meets Primary Endpoints for Insomnia Trial

February 18, 2020

Zelira Successfully Completes Capital Raising of $4.6M

February 4, 2020

December 2019 Quarterly Report

January 31, 2020

Zelira to Collaborate with the Parkinsons Foundation

January 27, 2020

Zelira Therapeutics expands HOPE distribution in the U.S.A

December 3, 2019

Ilera Therapeutics Merger Completed and Board Changes

December 1, 2019

Agreement with Health House to Distribute Zelda Products

November 20, 2019

Formulations to be supplied as part of CARE NSW trial

November 13, 2019

Zeldas Phase II Insomnia Clinical Trial Fully Enrolled

November 6, 2019

September 2019 Quarterly Report

October 31, 2019

Zelda to merge with US-based Ilera Therapeutics

October 8, 2019

Zeldas Autism Observational Study Recruits 100th Participant

August 21, 2019

June 2019 Quarterly Report

July 31, 2019

Zelda Collaborates with Emerald Clinics

July 18, 2019

Response to ASX Price and Volume Query

July 11, 2019

Zelda Granted Approval for Opioid Reduction Trial

July 1, 2019

March 2019 Quarterly Report

April 29, 2019

Zelda Partners with Ilera HealthCare

March 11, 2019

Aus Patent For Novel Prognostic Marker for Breast Cancer

March 5, 2019

Appendix 4D & FY19 Interim Financial Report

February 22, 2019

December 2018 Quarterly Report and Board Transition

January 30, 2019

ZLD to Invest in Development of Oral Spray Formulations

December 5, 2018

Opioid reduction clinical trial with St Vincents Hospital

November 25, 2018

September 2018 Quarterly Report

October 31, 2018

Zelda Focuses Clinical Trial Activity

October 10, 2018

US Autism Observational Study Underway

October 9, 2018

First Patient Dosed in Zelda Insomnia Trial

September 25, 2018

Zelda Forms New Partnership to Access German Market

September 3, 2018

June 2018 Quarterly Report

July 29, 2018

Commencement of New Managing Director

July 15, 2018

Appointment of Managing Director

May 21, 2018

March 2018 Quarterly Report

April 29, 2018

Insomnia Clinical Trial Update-Patient Recruitment Completed

April 22, 2018

Expansion of Pancreatic Cancer Research Programme

March 5, 2018

Appendix 4D & FY18 Interim Financial Report

February 27, 2018

Zelda joins with US Childrens Hospital for autism study

December 10, 2017

Australian Regulators Approve Zelda Insomnia Clinical Trial

November 28, 2017

Successful Results in Autism Observation Trial

September 17, 2017

Expansion of Breast Cancer Research Collaboration

July 31, 2017

Zelda Enters into Strategic Agreement with Knop Laboratories

June 14, 2017

Positive Results From Pre-Clinical Breast Cancer Studies

June 1, 2017

March 2017 Quarterly Report

April 28, 2017

Clinical Research Programme to Expand to Include Autism

April 18, 2017

Cleansing Prospectus

April 3, 2017

Zelda Successfully Completes Capital Raising

March 29, 2017

Zelda Enters Strategic Partnership with CannPal

March 26, 2017

Clinical Trials to Commence in Chile

March 22, 2017

New Licence Agreement

March 21, 2017

Appendix 4D & FY17 Interim Financial Report

February 27, 2017

← Newer news releases · Older news releases →

Decks

The 5 newest of 29 decks. Every deck is listed under its year.